Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus

Crit Rev Oncol Hematol. 2015 Oct;96(1):167-82. doi: 10.1016/j.critrevonc.2015.06.001. Epub 2015 Jul 2.

Abstract

The adverse effects of radiation therapy, often integrated with chemotherapy and/or targeted therapies, on the skin include severe acute and chronic dermatitis associated with pain, discomfort, itching, and burning, and may heavily affect patients' quality of life. The management of these skin adverse effects in head and neck cancer patients (HNCPs) are very heterogeneous due to the lack of shared rigorous classification systems and evidence based treatments. A multidisciplinary group of head and neck cancer specialists from Italy met with the aim of reaching a consensus on a clinical definition and management of dermatitis in HNCPs treated with radiotherapy with or without systemic therapies in order to improve skin toxicity management. The Delphi Appropriateness Method was used. External expert reviewers then evaluated the conclusions carefully according to their area of expertise. This paper offers contains seven clusters of statements about the management of dermatitis in HNCPs and a review of recent literature on these topics.

Keywords: Biodermatitis; Cetuximab; Chemotherapy; EGFRi; Head and neck cancer; Radiotherapy; Skin toxicity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cetuximab / adverse effects
  • Chemoradiotherapy / adverse effects*
  • Consensus
  • Dermatitis / etiology
  • Dermatitis / therapy*
  • ErbB Receptors / antagonists & inhibitors*
  • Head and Neck Neoplasms / therapy*
  • Humans
  • Pruritus / etiology
  • Risk Factors

Substances

  • ErbB Receptors
  • Cetuximab